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Two functions have been assigned to properdin; stabilization of
the alternative convertase, C3bBb, is well accepted, whereas the
role of properdin as pattern recognition molecule is controversial.
The presence of nonphysiological aggregates in purified properdin
preparations and experimental models that do not allow discrim-
ination between the initial binding of properdin and binding sec-
ondary to C3b deposition is a critical factor contributing to this
controversy. In previous work, by inhibiting C3, we showed that
properdin binding to zymosan and Escherichia coli is not a primary
event, but rather is solely dependent on initial C3 deposition. In
the present study, we found that properdin in human serum
bound dose-dependently to solid-phase myeloperoxidase. This
binding was dependent on C3 activation, as demonstrated by
the lack of binding in human serum with the C3-inhibitor compstatin
Cp40, in C3-depleted human serum, or when purified properdin is
applied in buffer. Similarly, binding of properdin to the surface of
human umbilical vein endothelial cells or Neisseria meningitidis after
incubation with human serum was completely C3-dependent, as de-
tected by flow cytometry. Properdin, which lacks the structural ho-
mology shared by other complement pattern recognition molecules
and has its major function in stabilizing the C3bBb convertase, was
found to bind both exogenous and endogenousmolecular patterns in
a completely C3-dependent manner. We therefore challenge the view
of properdin as a pattern recognition molecule, and argue that the
experimental conditions used to test this hypothesis should be
carefully considered, with emphasis on controlling initial C3 acti-
vation under physiological conditions.
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Properdin, also referred to as factor P, was first described in1954 by Pillemer and colleagues as a component that, in an
antibody-independent manner, is able to promote complement
activation on zymosan particles and on other carbohydrates (1).
These claims were controversial, and properdin-dependent
complement activation was dismissed by the scientific commu-
nity (2–4); however, the “properdin system” was reborn as the
alternative pathway (AP) more than 20 y later (3), with pro-
perdin described as a stabilizer and positive regulator of the AP
C3 convertase (5, 6). Properdin and its possible different roles in
complement activation have been a basis for further studies in
this area (7–11).
In the current conception, although yet to be proven in vivo,
the AP of the complement system is slowly autoactivated via
spontaneous or induced formation of fluid-phase AP C3 convertase
(12, 13). The C3 moiety within this convertase is C3(H2O) formed
on exposure and subsequent hydrolysis of the internal thioester,
which is normally protected inside native C3 (14-16). C3(H2O) is
“C3b-like”; it still contains C3a, but is conformationally similar
to C3b. C3(H2O) can bind factor B, which is cleaved by factor D
into Ba and Bb. Bb remains bound to C3(H2O), forming the
enzymatic complex that cleaves C3 into C3b and C3a. Surface-
bound C3b can form additional AP C3 convertase molecules
with Bb, which rapidly cleave more C3 resulting in self-amplifi-
cation and generation of the C5 convertase C3bBbC3b. The
degree of amplification on a surface is determined by the rate of
the C3b feedback (i.e., C3 cleavage) and breakdown (i.e., C3b
degradation) cycles (17).
We previously reported that amplification via the AP on an
unprotected surface contributes to more than 80% of terminal
pathway activation after specific initial classical pathway or lectin
pathway activation (18, 19). The C3bBb complex is relatively
unstable, with a half-life of 90 s under physiological conditions
(6, 20); however, properdin can associate with C3bBb and create
the more stable C3bBbP complex that is essential for effective
AP amplification (5, 21). Recently published electron microcopy
images of the C3bBbP complex have shown how properdin is
associated with the convertase near the C345C domain of C3b
and the von Willebrand factor type A domain of factor B (22).
Discussion of the role of properdin as a pattern recognition
molecule and initiator of the AP was renewed with experiments
showing that purified unfractionated properdin covalently at-
tached to a biosensor surface could serve as a platform for in
situ assembly of the AP C3 convertase (23). This was done in a
relatively artificial system by using purified components in
buffer milieu. That study was followed by several reports of
biological substrates suggested to serve as patterns for the
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direct recognition by properdin for AP complement activation.
Reported patterns include exogenous microorganisms (7, 24),
endogenous cells (25–27), and various biological substrates (9,
28, 29); however, many of these experiments were performed in
systems permitting either C3 activation with initial C3b de-
position or in buffer systems with purified properdin. In the
presence of intact C3, it is virtually impossible to demonstrate
whether properdin acts in a recognition manner or subsequently
binds to C3b. On the other hand, purified properdin is sensitive
to aggregation into sticky multimers, and these aggregates, re-
ferred to as activated properdin, do not behave as the native
form; thus, results with purified properdin must be judged with
care (30, 31), especially in unfractionated preparations (32).
Early preparations of properdin, such as those used in the initial
studies by Pillemer et al. (1), were later shown to contain im-
purities and high molecular aggregates of properdin, which were
lost when adsorption to zymosan was omitted from the purifi-
cation protocols (30, 33, 34). Furthermore, it is crucially im-
portant to distinguish between passive binding of properdin to a
surface and subsequent activation of AP as a result of this
binding. For this purpose, the methodological conditions should
be under strict control.
In previous work, by inhibiting C3 cleavage with the peptide
inhibitor compstatin Cp40, we showed that properdin binding to
zymosan and Escherichia coli is not a primary event, but is
completely dependent on initial C3 deposition (35). In the present
study, we aimed to investigate whether the binding of properdin to
other tentative targets for pattern recognition, i.e., granulocyte
myeloperoxidase (MPO), human umbilical vein endothelial cells
(HUVECs), and Neisseria meningitidis, is a primary event or de-
pendent on C3 deposition. For this purpose, we compared normal
human serum (NHS) with and without compstatin Cp40, as well as
C3-depleted human serum with and without reconstitution of
purified C3.
Results
Properdin Binding to MPO-Coated Wells After Incubation with Human
Serum. Owing to the retained peroxidase activity of immobilized
MPO, the binding of properdin to MPO-coated wells was not
possible to evaluate in our regular ELISA with HRP-labeled
detection antibody and substrate dependent on peroxidase ac-
tivity. Thus, a detection system based on alkaline phosphatase-
labeled anti-mouse IgG antibody was developed. A pool of NHS
incubated in serial dilutions on the MPO coat led to a dose-
dependent binding of properdin (Fig. 1A). In contrast to pro-
perdin-containing NHS, there was minimal binding of purified
properdin using a concentration corresponding to that in NHS
(OD = 1.35 vs. 0.17), with a signal similar to that of the buffer
control (OD = 0.12) (Fig. 1B).
MPO-Induced Terminal Pathway Activation and Dependency on C3.
MPO was previously shown to activate complement via the AP
(28). MPO coated onto microtiter plates activated complement,
as detected by binding of the monoclonal antibody aE11, specific
for a C9 neoepitope in the terminal C5b-9 complement complex
(36). No generation of C5b-9 on the surface by MPO occurred in
human serum depleted of C3 (OD = 0.13); however, on re-
constitution with purified C3, a strong deposition of C5b-9 was
found (OD = 0.81), which was efficiently blocked by compstatin
Cp40 (OD = 0.13) (Fig. 2A).
C3-Dependent Binding of Properdin to MPO. We next examined C3
dependence for the binding of properdin to MPO. Binding of
properdin in NHS to MPO was completely abolished when C3
cleavage was inhibited with compstatin Cp40 (OD = 2.92 vs.
0.15) (Fig. 2B, Left). Similarly, no binding of properdin occurred
from C3-depleted human serum, but binding was restored by
reconstitution with purified C3 (OD = 0.10 vs. 1.44) (Fig. 2B,
Middle). This binding was abrogated in the presence of comp-
statin Cp40 (OD = 0.10).
We then assessed binding in properdin-depleted serum before
and after reconstitution with purified properdin in the presence
and absence of compstatin Cp40 (Fig. 2B, Right). Properdin
binding was achieved when properdin-depleted human serum
was reconstituted with purified properdin (OD = 1.33), but was
again completely dependent on C3 cleavage, as demonstrated by
the fact that compstatin Cp40 reduced the binding to background
level (OD = 0.17). The purified properdin used was stored at
−70 °C and thawed only once for the experiments. Because the
composition and quality of the purified properdin preparation
used in these experiments are crucial for correct interpretation
of the data, we performed a careful characterization of the
purified properdin preparation by exclusion chromatography,
Fig. 1. Binding of properdin to immobilized MPO. NHS in serial dilutions
(A) or purified properdin diluted in VBS buffer (B) was incubated in micro-
titer plates coated with human neutrophil MPO dissolved in 0.05 M Na2CO3,
pH 9.5, by overnight incubation at room temperature, or incubated solely
with 0.05 M Na2CO3 as a control. All wells were subsequently blocked with
1.0% BSA in PBS (pH 7.4) and Tween (0.1%) for 60 min. NHS, serially diluted
in 2.5 mM VBS, pH 7.2, with MgEGTA or purified properdin (2 μg/mL in VBS/
MgEGTA), was incubated on MPO-coated surfaces or controls for 60 min at
37 °C. Binding of properdin was demonstrated in ELISA with mouse anti-
human properdin. Data are presented as mean with 95% CI OD values for six
experiments. ***P < 0.001.



























SDS/PAGE, and Western blot analysis, as described in SI Ma-
terials and Methods and shown in Fig. S1.
C3-Dependent Binding of Properdin to HUVECs.We tested HUVECs
incubated with NHS for the binding of C3d and properdin. In-
cubation for 4 h on HUVECs resulted in substantial deposition
of C3d fragments detected by flow cytometry, with a median
fluorescence intensity (MFI) of 813 (Fig. 3 A and B). In the
presence of compstatin Cp40, C3d deposition was virtually
abolished (>97%). Properdin binding on HUVECs followed the
same trend and was largely dependent on C3 (Fig. 3 C and D). In
the presence of compstatin Cp40, properdin binding from NHS
was reduced by 90%, from an MFI of 40.6 to an MFI of 16.7, a
value in the same range as the isotype control (MFI = 13.9).
Controls with properdin- and C3-depleted human serum showed
comparably low values with a distinct increase in properdin
binding after reconstitution with purified properdin and C3, re-
spectively (Fig. 3E).
C3-Dependent Binding of Properdin to N. meningitidis. Binding of
properdin from NHS to N. meningitidis was evaluated by flow
cytometry. Incubation of N. meningitidis in NHS diluted 1:2
yielded a distinct signal for deposition of properdin on the bac-
teria (MFI = 31.2) (Fig. 4 A and B). The addition of compstatin
Cp40 abrogated this deposition completely (MFI = 3.6), showing
values similar to the isotype control (MFI = 3.8). Virtually
identical findings were seen with C3-depleted human serum (Fig.
4 C and D). After exposure of N. meningitidis to C3-depleted
human serum, properdin deposition was in the range of the
isotype control (MFI = 4.3). Reconstitution of C3-depleted
Fig. 2. C3 dependence for complement activation and properdin binding
on MPO. (A) NHS and C3-depleted human serum diluted 1:5 with and
without purified C3 (130 μg/mL) were incubated on MPO-coated wells (gray
bars) or uncoated wells (white bars) in the presence or absence of compstatin
Cp40. Complement activation triggered by MPO was detected as surface de-
position of C5b-9 using the monoclonal antibody aE11, specific for a C9 neo-
epitope in C5b-9. (B) The same experimental setup as in A, but also including
properdin-depleted human serum diluted 1:5 with and without properdin
(2 μg/mL), was tested for the binding of properdin to MPO. Properdin was
detected as in ELISA with mouse anti-human properdin. Data are presented
as mean with 95% CI OD values of six experiments. ***P < 0.001.
Fig. 3. C3 deposition and binding of properdin to the surface of HUVECs.
Undiluted NHS with and without compstatin Cp40 (A–D) or human serum
depleted and reconstituted for C3 or properdin (E) was incubated for 4 h at
37 °C on monolayers of confluent HUVECs. Deposition of C3d fragments
(A and B) and binding of properdin (C–E) were analyzed by flow cytometry.
A and C show representative curves for binding of C3d and properdin
(continuous lines), respectively, to HUVECs in NHS (gray background) or NHS
with compstatin Cp40 (white background), or in NHS binding of the isotype
control (dotted line). B and D show individual values and mean with 95% CI
of six experiments. *P < 0.05; **P < 0.01. Stippled lines represent the range
for binding of the isotype control. E shows the mean ± SD value of six
experiments.
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human serum with purified C3 showed binding approaching the
levels in NHS (MFI = 15.1).
Discussion
In the present study, we have demonstrated that properdin is
unable to bind directly to granulocyte MPO, to the surface of
HUVECs, or to N. meningitidis, but that the interaction is fully
dependent on initial C3 activation and thus does not act as a
pattern recognition molecule for these targets. We investigated
these targets because some interesting observations regarding
the interaction between them and properdin have been reported.
MPO was recently reported to directly attract serum properdin
for initiation of the AP (28). N. meningitidis and endothelial cells
were studied based on their central role in properdin patho-
physiology. Properdin is significant in the defense against Neis-
seria species, and Neisseria gonorrhea was claimed to directly bind
properdin (7), findings that have been extrapolated to N. men-
ingitidis (37). Endothelial cells are a source of serum properdin
(38), and properdin has been shown to interact with various
glycosaminoglycans on endogenous cells (25, 39, 40).
In a previous study, we showed that inhibition of C3 cleavage
could serve to distinguish between the primary binding of pro-
perdin (i.e., pattern recognition function) and properdin binding
secondary to initial C3 fragment deposition (i.e., convertase
stabilization) (35). Using the C3 inhibitor compstatin Cp40, we
consistently found that properdin in human serum and properdin
released from activated polymorphonuclear leukocytes did not
bind directly to zymosan or E. coli, but that binding of properdin
was fully dependent on the initial deposition of C3b. By using the
same principle here, properdin binding to MPO, HUVECs, and
N. meningitidis was found to be fully dependent on accessible C3.
Thus, the addition of a C3 inhibitor, compstatin Cp40, to NHS or
the use of C3-depleted serum did not show any direct binding of
properdin to these five different tested surfaces and ligands that
we tested, of which three were exogenous and two were endog-
enous, supporting the notion that properdin is not a promiscuous
molecule binding to various “danger” ligands.
The background of the present study was the controversy
surrounding properdin acting as a pattern recognition molecule
in activation of the AP. Properdin lacks the structural homology
shared by other pattern recognition molecules of the comple-
ment system. C1q and the recognition molecules of the lectin
pathway, including mannose-binding lectin, ficolins, and collectins,
all have a common structure with a bouquet of globular heads built
up of a cysteine-rich N-terminal stretch, a collagen-like domain,
and a carbohydrate-recognition domain or fibrinogen-like domain
(41). These molecules bind their respective targets with high
avidity using multiple sites for interaction (42, 43). This is distinctly
different from properdin, which is a linear molecule composed of
repeating thrombospondin type I domains (44), a noteworthy
difference from the typical fluid-phase pattern recognition mol-
ecules of innate immunity. Although this does not completely
exclude properdin for recognizing certain structures besides the
AP convertase, it is in line with our findings, making it unlikely
that properdin can be defined as a recognition molecule.
Indications of the role of properdin as pattern recognition
molecule started with experiments showing that purified pro-
perdin covalently bound to a biosensor surface could serve as a
platform for the in situ assembly of AP C3 convertases (23).
Initial data introduced the attractive concept of how properdin
could not only stabilize the C3bBb convertase, but also promote
surface attraction of preformed fluid-phase C3bBb; however,
studies using surface plasmon resonance depend on the use of
purified proteins in a buffer system, which introduces a certain
degree of artificiality. Properdin in purified preparations is prone
to aggregation, and extrapolating findings on covalently bound
properdin to native serum properdin interacting on a biological
substrate is virtually impossible. Nonetheless, later data indicated
that AP is indeed initiated by the noncovalent attachment of
properdin on surfaces of different microorganisms, including
yeast cell walls, N. gonorrheae, and LPS-negative E. coli (7).
However, these experiments were performed in a system per-
mitting autoactivation of C3 (12, 45) and allowing slow, contin-
uous surface C3b deposition, thus making it difficult to
determine whether properdin reacts primarily to the activating
surface as a true pattern recognition molecule or binds second-
arily to C3b.
Agarwal et al. (46) later extensively studied the ability of
several strains of N. gonorrheae and N. meningitidis to directly
bind properdin. None of the tested strains bound native pro-
perdin, but binding did occur with purified preparations of
properdin containing high-order oligomers of aggregated pro-
perdin, a phenomenon later demonstrated on zymosan and
Streptococcus pneumonia as well (46, 47). Aggregates of pro-
perdin were shown to appear spontaneously in certain purified
preparations on preparation or during long-term storage or
freezing and thawing (30, 31). These aggregates are artifacts with
different properties than serum properdin; for example, they
promote fluid-phase complement activation and C3 depletion, as
illustrated by the old term “activated properdin” (30, 31). Ali
et al. (47) recently showed that recombinant highly polymerized
properdin can be a powerful agent to therapeutically combat
infections by N. meningitidis and S. pneumonia. Mice infected
with these bacteria were protected when given recombinantly
expressed properdin containing high-order oligomers, which, in
Fig. 4. Binding of properdin to the surface of N. meningitidis. Heat-inac-
tivated N. meningitidis (reference strain 44/76), suspended in VBS with MgCl2
(0.5 mM), CaCl2 (2 mM), and gelatin (0.1%), pH 7.5, were incubated in NHS
(diluted 1:2) in the presence or absence of compstatin Cp40 (A and B) or in
C3-depleted human serum (diluted 1:2) with and without purified C3
(650 μg/mL) (C and D) at 37 °C for 20 min. Binding of properdin was detected
by a monoclonal antibody using flow cytometry. A and C show representa-
tive curves for the binding of anti-properdin (continuous line) to bacteria in
NHS (gray background) or human serum inhibited/depleted of C3 (white
background), or in NHS binding of the isotype control (dotted line). B and D show
individual values and the mean with 95% CI value of five experiments. ***P <
0.001. Stippled lines represent the range for binding of the isotype control.



























contrast to low-order oligomers of properdin in plasma, directly
interact with the bacterial surface and focus C3b deposition (47).
In contrast to our findings with exogenous ligands, previously
shown with zymosan and E. coli (35) and in the present work with
N. meningitidis, there is evidence of C3- independent properdin
binding to ligands on endogenous cells, such as DNA on late
apoptotic or necrotic cells (26), and presumably various glycos-
aminoglycans on early apoptotic T cells, but not necrotic T cells
(25), activated platelets (27), and renal tubular epithelial cells
(39, 40). To the best of our knowledge, no data for endothelial
cells and properdin binding have been reported previously, even
though endothelial cells are a source of serum properdin and can
express heparin sulfate proteoglycans, which have been shown to
bind properdin (39, 48). In the present study, after incubation of
human serum on HUVECs for 4 h, surface complement activa-
tion was detected as deposition of C3d fragments on the cells.
Properdin was also found on the cells, but, like for N. meningi-
tidis, this binding was dependent on initial C3 activation, because
compstatin Cp40 almost entirely inhibited properdin binding.
Recently, MPO was added to the list of suggested endogenous
molecules capable of binding properdin directly (28). Thus,
MPO could be the molecule that links properdin binding to the
surface of activated neutrophils, as has been reported previously
(49). By studying properdin binding to immobilized MPO, the
authors proposed that MPO promotes complement activation by
directly binding properdin (49). We question those findings,
however, because they were based on a detection system using
HRP-labeled antibodies in which we found it impossible to distin-
guish substrate turnover caused by peroxidase activity by the anti-
body-linked HRP and that caused by the immobilized MPO. By
changing the enzyme and substrate in the detection system, we
showed that properdin was not attracted to MPO in the absence or
inhibition of C3; however, immobilized MPO did serve as an ex-
cellent complement activator by promoting the formation of C5b-9
on the surface and, in the presence of C3, the binding of properdin.
In conclusion, we challenge the view of properdin as a pattern
recognition molecule by providing evidence that it binds to dif-
ferent exogenous and endogenous molecular patterns in only a
C3-dependent manner. To support the claim that properdin is a
pattern recognition molecule, it should be clearly shown that the
initial binding and subsequent activation are C3-independent,
and the use of purified properdin preparations should be criti-
cally evaluated. Taken together, our data provide further support
for the role of properdin as a specific stabilizer of the AP C3
convertase that generally does not act as a recognition molecule.
Materials and Methods
Antibodies and Other Reagents. Two mouse anti-human properdin IgG1κ
antibodies (P1: A233 and P2: A235) were obtained from Quidel, and anti-C3d
clone 7C10 was obtained from Abcam. Clone IS7 (IgG1κ, anti-human CD22),
from Diatec Monoclonals, served as an isotype control for IgG1κ. Monoclonal Ab
aE11, specifically binding a C9 neoepitope in the terminal C5b-9 complement
complex (50), was obtained from Diatec Monoclonals. Clone 5A7, from Diatec
Monoclonals, served as an IgG2a isotype control. Sheep F(ab′)2 alkaline phos-
phatase-labeled anti-mouse IgG was obtained from Sigma-Aldrich, F(ab′)2 anti-
mouse IgG-FITC was obtained from GE Healthcare UK, goat anti-mouse IgG1-
FITC was obtained from Southern Biotech, and goat anti-mouse was obtained
from Jackson ImmunoResearch. The compstatin analog Cp40 (dTyr-Ile-[Cys-Val-
Trp(Me)-Gln-Asp-Trp-Sar-His-Arg-Cys]-mIle-NH2), used specifically to block C3
cleavage (51), was a kind gift from John D. Lambris, University of Pennsylvania,
Philadelphia.
Serum and Purified Proteins. NHS was collected from nine healthy volunteers,
all of whomwere normal in classical pathway, lectin pathway, and AP activity,
as detected by the Wieslab total complement system screen assay (Euro
Diagnostica) (52). Sera were pooled and stored in aliquots at –70 °C. Pro-
perdin-depleted human serum and purified properdin were obtained from
Complement Technology. The properdin was characterized by size- exclusion
chromatography, SDS/PAGE, and Western blot analysis. Properdin was
quantified in serum and in C3-depleted human serum as 15.8 and 14.6 μg/mL,
respectively, using a human properdin ELISA kit (Hycult Biotech) according to
the manufacturer’s instructions. C3-depleted human serum and purified C3
were obtained from Complement Technology and Quidel, respectively. Human
neutrophil MPO was obtained from Athens Research & Technology.
Endothelial Cells.HUVECs were isolated from umbilical cord veins by digestion
with 0.1% collagenase A (Roche Diagnostics) and cultured as described
previously (53). Confluent HUVECs in passages two through five were used in
the experiments.
Bacteria. The N. meningitidis reference strain 44/76 was used here. It is
characterized as B:15:P1.7,16:L3,7,9, belonging to the multilocus sequence
type 32 clone (previously electrophoretic type 5). This reference strain was
originally isolated from a woman admitted to Ullevål University Hospital,
Oslo, Norway, with lethal meningococcal infection in 1976 and is the pro-
totype bacterium of the clone causing the long-lasting Norwegian epi-
demics. The bacteria were grown overnight on Colombia agar, resuspended
in sterile PBS, heat-inactivated at 56 °C for 30 min and frozen at −70 °C until
use. Heat-inactivated bacteria were used for safety reasons. Heat inactiva-
tion causes only minor alterations to the bacterial membrane, and the bi-
ological activity is preserved (54).
Binding of Properdin to MPO. Microtiter plates (Costar high-binding; Corning)
were coated with MPO (20 μg/mL, dissolved in 0.05 M NaCO3, pH 9.5) by
overnight incubation at room temperature, or incubated solely with 0.05 M
NaCO3 as a control. All wells were subsequently blocked with 1% BSA in PBS
(pH 7.4) and Tween (0.1%) for 60 min. NHS, serially diluted in 2.5 mM
veronal-buffered saline (VBS), pH 7.2, with MgEGTA (5 mMMg2+ and 10 mM
EGTA) or purified properdin (2 μg/mL in VBS/MgEGTA) were incubated on
MPO-coated surfaces or controls for 60 min at 37 °C. In separate sets of
experiments, incubation was done on MPO-coated surfaces with NHS (1:5)
with or without compstatin Cp40 (8 μM), on C3-depleted serum (1:5) with or
without purified C3 (130 μg/mL), and on properdin-depleted serum (1:5)
with or without purified properdin (2 μg/mL). Binding of properdin was
detected with mAb anti-properdin (1:1,000), followed by alkaline phos-
phatase-labeled sheep F(ab′)2 anti-mouse IgG (whole molecule) (1:1,000).
Deposition of C5b-9 onto MPO surfaces or controls after incubation with
NHS with or without compstatin Cp40 or with C3-depleted serum with or
without purified C3 was detected with mAb aE11 (1 mg/mL; 1:6,000), followed
by alkaline phosphatase-labeled sheep anti-mouse IgG. p-nitrophenyl phos-
phate (pNPP; Sigma-Aldrich) served as a substrate for alkaline phosphatase.
Binding of Properdin to N. meningitidis. N. meningitidis were washed by re-
peated centrifugation at 3,220 × g for 10 min and then resuspended in PBS
with 0.1% BSA. Bacteria were then suspended in VBS with MgCl2 (0.5 mM),
CaCl2 (2 mM), and gelatin (0.1%), pH 7.5. NHS was preincubated with or
without compstatin Cp40 (40 μM) for 5 min and then added to the bacteria
(final dilution, 1:2) and incubated at 37 °C for 20 min. Binding of properdin
was evaluated with mAb anti-properdin (diluted 1:50) or isotype control
clone IS7, followed by F(ab′)2 anti-mouse IgG-FITC (1:50). Samples were washed
twice, resuspended in PBS with 1% BSA, and analyzed on a FACSCalibur flow
cytometer (BD Biosciences). N. meningitidis was gated on forward-scatter
and side-scatter, and 20,000 events were collected. Data were evaluated
using FlowJo version 10.
Binding of Properdin to HUVECs. Confluent HUVECs were washed twice with
tempered PBS, pH 7.4. NHS with or without compstatin Cp40 (40 μM) was
incubated on a monolayer of HUVECs in cell culture plates for 4 h at 37 °C.
HUVECs were also incubated with C3-depleted human serum with and without
purified C3 (650 μg/mL) or with properdin-depleted human serum with and
without properdin (10 μg/mL) as a control. After incubation, cells were washed
twice with ice-cold PBS and then fixed for 2.5 min with 0.5% paraformaldehyde.
Binding of C3 fragments and properdin was evaluated using mAbs against C3d
and properdin, respectively, or the isotype control clone IS7, all followed by goat
anti-mouse IgG1-FITC. Cells were then trypsinated, washed, and run on a
FACSCalibur flow cytometer. Data were analyzed with FlowJo version 10.
Statistics.GraphPad Prism version 5was used for statistical analyses. Statistical
differenceswere analyzed on normally distributed data using the Student t test or,
when more than two conditions were compared, with one-way ANOVA followed
by the Bonferroni posttest. A P value <0.05 was considered statistically significant.
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